Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

PUBLICATION DATE

4 results
Display

Salvage chemotherapy with R-BAD (rituximab, bendamustine, cytarabine, and dexamethasone) for the treatment of relapsed primary CNS lymphoma

Cho MS, Kim JY, Jung SY, Ahn SY, Song GY, Yang DH

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Bendamustine, etoposide, and dexamethasone to mobilize peripheral blood hematopoietic stem cells for autologous transplantation in non-Hodgkin lymphoma

Greenbaum , Green DJ, Holmberg L, Gooley T, Till BG, Budde LE, Rasmussen , Press OW, Gopal AK

BACKGROUND: Bendamustine is a chemotherapeutic agent that has shown broad activity in patients with lymphoid malignancies. It contains both alkylating and nucleoside analog moieties, and thus, is not commonly used...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Bendamustine in heavily pre-treated multiple myeloma patients: Results of a retrospective analysis from the Korean Multiple Myeloma Working Party

Kim SJ, Bang SM, Choi YS, Jo DY, Kim JS, Lee H, Eom HS, Yoon DH, Suh C, Lee JJ, Hong J, Lee JH, Koh Y, Kim K, Yoon SS, Min CK, Korean Multiple Myeloma Working Party

BACKGROUND: Bendamustine may be a potential treatment option for patients with myeloma, but little is known about the utility of bendamustine as a salvage treatment, especially in Asian patients. METHODS: We...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Safety and efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with relapsed/refractory lymphoma

Shabbir-Moosajee M, Jehangir S, Sawani S, Muhammed T, Ali N, Sheikh U, Adil S

BACKGROUND: Bendamustine is an attractive option for the management of both de novo and relapsed lymphomas. It is being increasingly used in the conditioning regimen for autologous stem cell transplantation...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2025 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr